Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

ALX Oncology

Status and phase: Active, not recruiting; Phase 2

Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma

Treatments: Drug: Cisplatin/Carboplatin; 5FU; Drug: pembrolizumab; Drug: evorpacept

Study type: Interventional

Funder types: Industry

Identifiers

NCT04675333

MK-3475-B88 (Other Identifier)

2020-004662-19 (EudraCT Number)

AT148004

KEYNOTE-B88 (Other Identifier)

Details and patient eligibility

About

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Full description

This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.

Enrollment: 172 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Previously untreated metastatic or unresectable, recurrent head and neck squamous cell carcinoma.
• Adequate bone marrow function.
• Adequate renal and liver function.
• Adequate ECOG performance status.

Exclusion criteria

• Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
• History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
• Prior treatment with any anti-CD47 or anti-SIRPα agent.
• Prior treatment with anti-PD-1 or PD-L1.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

172 participants in 2 patient groups

evorpacept (ALX148) + pembrolizumab + Chemotherapy

Experimental group

Description:

evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.

Treatment:

Drug: evorpacept

Drug: pembrolizumab

Drug: Cisplatin/Carboplatin; 5FU

pembrolizumab + Chemotherapy

Active Comparator group

Description:

pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.

Treatment:

Drug: pembrolizumab

Drug: Cisplatin/Carboplatin; 5FU